The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
Open accessAbstract
Histone H3K36 trimethylation (H3K36me3) is frequently lost in multiple cancer types, identifying it as an important therapeutic target. Here we identify a synthetic lethal interaction in which H3K36me3-deficient cancers are acutely sensitive to WEE1 inhibition. We show that RRM2, a ribonucleotide reductase subunit, is the target of this synthetic lethal interaction. RRM2 is regulated by two pathways here: first, H3K36me3 facilitates RRM2 expression through transcription initiation factor recruitment; second, WEE1 inhibition degrades RRM2 through untimely CDK activation. Therefore, WEE1 inhibition in H3K36me3-deficient cells results in RRM2 reduction, critical dNTP depletion, S-phase arrest, and apoptosis. Accordingly, this synthetic lethality is suppressed by increasing RRM2 expression or inhibiting RRM2 degradation. Finally, we demonstrate that WEE1 inhibitor AZD1775 regresses H3K36me3-deficient tumor xenografts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“SETD2 mutations and KDM4A overexpression are together observed in more than 10% of cancers in kidney, large intestines, endometrium, and ovary (Berry and Janknecht, 2013; Dalgliesh et al., 2010; Gerlinger et al., 2012).”
BackgroundTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345 · cited 6×
“In both cases, U2OS cells were sensitized to AZD1775 (KDM4A IC50 = 106 nM, K36M IC50 = 117 nM versus control IC50 > 400 nM) (Figure 1F).”
InfluentialIntegrated molecular analysis of clear-cell renal cell carcinoma
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato-Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,221
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08672 · Cited by 1,173 · cited 1×
“SETD2 mutations and KDM4A overexpression are together observed in more than 10% of cancers in kidney, large intestines, endometrium, and ovary (Berry and Janknecht, 2013; Dalgliesh et al., 2010; Gerlinger et al., 2012).”
BackgroundShilatifard, A. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142422 · Cited by 1,103
Vermeulen, M., Eberl, H. C., Matarese, F., Marks, H., Denissov, S., Butter, F., Lee, K. K., Olsen, J. V., Hyman, A. A., Stunnenberg, H. G., et al. (2010) · Cell · doi:10.1016/j.cell.2010.08.020 · Cited by 806
Inactivation of the p34 cdc2 -Cyclin B Complex by the Human WEE1 Tyrosine Kinase
Parker, L. L., & Piwnica-Worms, H. (1992) · Science · doi:10.1126/science.1384126 · Cited by 716
Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks
Aymard, F., Bugler, B., Schmidt, C. K., Guillou, E., Caron, P., Briois, S., Iacovoni, J. S., Daburon, V., Miller, K. M., Jackson, S. P., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2796 · Cited by 668
Jin, J., Arias, E. E., Chen, J., Harper, J. W., & Walter, J. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.010 · Cited by 632
Begg, A. C., McNally, N. J., Shrieve, D. C., & Kärche, H. (1985) · Cytometry · doi:10.1002/cyto.990060618 · Cited by 587
Paulsen, R. D., Soni, D. V., Wollman, R., Hahn, A. T., Yee, M.-C., Guan, A., Hesley, J. A., Miller, S. C., Cromwell, E. F., Solow-Cordero, D. E., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.021 · Cited by 555
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
Pfister, S. X., Ahrabi, S., Zalmas, L.-P., Sarkar, S., Aymard, F., Bachrati, C. Z., Helleday, T., Legube, G., La Thangue, N. B., Porter, A. C. G., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.026 · Cited by 463
Self-citationRegulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle.
Watanabe, N., Broome, M., & Hunter, T. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07180.x · Cited by 450
KDM4/JMJD2 Histone Demethylases: Epigenetic Regulators in Cancer Cells
Berry, W. L., & Janknecht, R. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4300 · Cited by 447
D'Angiolella, V., Donato, V., Forrester, F. M., Jeong, Y.-T., Pellacani, C., Kudo, Y., Saraf, A., Florens, L., Washburn, M. P., & Pagano, M. (2012) · Cell · doi:10.1016/j.cell.2012.03.043 · Cited by 395
Self-citationHanada, K., Budzowska, M., Davies, S. L., van Drunen, E., Onizawa, H., Beverloo, H. B., Maas, A., Essers, J., Hickson, I. D., & Kanaar, R. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1313 · Cited by 390
Hakimi, A. A., Ostrovnaya, I., Reva, B., Schultz, N., Chen, Y.-B., Gonen, M., Liu, H., Takeda, S., Voss, M. H., Tickoo, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3886 · Cited by 357
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Aarts, M., Sharpe, R., Garcia-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., Toniatti, C., Ashworth, A., & Turner, N. C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0320 · Cited by 327
Sorensen, C. S., & Syljuasen, R. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr697 · Cited by 318
Beck, H., Nähse-Kumpf, V., Larsen, M. S. Y., O'Hanlon, K. A., Patzke, S., Holmberg, C., Mejlvang, J., Groth, A., Nielsen, O., Syljuåsen, R. G., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00412-12 · Cited by 306
Jones, R. M., Mortusewicz, O., Afzal, I., Lorvellec, M., García, P., Helleday, T., & Petermann, E. (2013) · Oncogene · doi:10.1038/onc.2012.387 · Cited by 295
Fontebasso, A. M., Schwartzentruber, J., Khuong-Quang, D.-A., Liu, X.-Y., Sturm, D., Korshunov, A., Jones, D. T. W., Witt, H., Kool, M., Albrecht, S., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1095-8 · Cited by 290
Self-citationSETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint
Carvalho, S., Vítor, A. C., Sridhara, S. C., Martins, F. B., Raposo, A. C., Desterro, J. M., Ferreira, J., & de Almeida, S. F. (2014) · eLife · doi:10.7554/elife.02482 · Cited by 265
Harnessing synthetic lethal interactions in anticancer drug discovery
Chan, D. A., & Giaccia, A. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3374 · Cited by 262
Identification of functional cooperative mutations of SETD2 in human acute leukemia
Zhu, X., He, F., Zeng, H., Ling, S., Chen, A., Wang, Y., Yan, X., Wei, W., Pang, Y., Cheng, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.2894 · Cited by 247
Black, J. C., Manning, A. L., Van Rechem, C., Kim, J., Ladd, B., Cho, J., Pineda, C. M., Murphy, N., Daniels, D. L., Montagna, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.051 · Cited by 212
Sherman, P. A., & Fyfe, J. A. (1989) · Analytical Biochemistry · doi:10.1016/0003-2697(89)90420-x · Cited by 211
Sirbu, B. M., Couch, F. B., & Cortez, D. (2012) · Nature Protocols · doi:10.1038/nprot.2012.010 · Cited by 207
Kanu, N., Grönroos, E., Martinez, P., Burrell, R. A., Yi Goh, X., Bartkova, J., Maya-Mendoza, A., Mistrík, M., Rowan, A. J., Patel, H., et al. (2015) · Oncogene · doi:10.1038/onc.2015.24 · Cited by 181
Chabes, A., & Thelander, L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000799200 · Cited by 178
Carvalho, S., Raposo, A. C., Martins, F. B., Grosso, A. R., Sridhara, S. C., Rino, J., Carmo-Fonseca, M., & de Almeida, S. F. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1472 · Cited by 175
Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase
Beck, H., Nähse, V., Larsen, M. S. Y., Groth, P., Clancy, T., Lees, M., Jørgensen, M., Helleday, T., Syljuåsen, R. G., & Sørensen, C. S. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200905059 · Cited by 169
A histone H3K36 chromatin switch coordinates DNA double-strand break repair pathway choice
Pai, C.-C., Deegan, R. S., Subramanian, L., Gal, C., Sarkar, S., Blaikley, E. J., Walker, C., Hulme, L., Bernhard, E., Codlin, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms5091 · Cited by 165
Self-citationCVT-313, a Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation
Brooks, E. E., Gray, N. S., Joly, A. H., Kerwar, S. S., Lum, R. T., Mackman, R. L., Norman, T., Rosete, J., Rowe, M. W., Schow, S. R., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.46.29207 · Cited by 143
Linden, A. A. V., Baturin, D., Ford, J. B., Fosmire, S. P., Gardner, L. A., Korch, C. T., Reigan, P., & Porter, C. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0424 · Cited by 130
Sarakbi, W. A., Sasi, W., Jiang, W. G., Roberts, T., Newbold, R. F., & Mokbel, K. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-290 · Cited by 121
Tominaga, Y., Li, C., Wang, R., & Deng, C. (2006) · International Journal of Biological Sciences · doi:10.7150/ijbs.2.161 · Cited by 93
Zhang, Y., Xie, S., Zhou, Y., Xie, Y., Liu, P., Sun, M., Xiao, H., Jin, Y., Sun, X., Zhu, C. H., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.031 · Cited by 79
Shimura, T., Torres, M. J., Martin, M. M., Rao, V. A., Pommier, Y. G., Katsura, M., Miyagawa, K., & Aladjem, M. I. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.11.006 · Cited by 71
p53 Regulation and Function in Renal Cell Carcinoma
Warburton, H. E., Brady, M., Vlatković, N., Linehan, W. M., PARSONS, K. F., & Boyd, M. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0017 · Cited by 63
Aarts, M., Bajrami, I., Herrera-Abreu, M. T., Elliott, R. J. R., Brough, R., Ashworth, A., Lord, C. J., & Turner, N. C. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0845 · Cited by 63
Cited by
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Blackford, A. N., & Jackson, S. P. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.015 · Cited by 1,961
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Targeting DNA damage response pathways in cancer
Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 836
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
Jonasch, E., Walker, C. L., & Rathmell, W. K. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00359-2 · Cited by 644
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420
Metadata
- Authors
- Pfister, S. X., Markkanen, E., Jiang, Y., Sarkar, S., Woodcock, M., Orlando, G., Mavrommati, I., Pai, C.-C., Zalmas, L.-P., Drobnitzky, N., Dianov, G. L., Verrill, C., Macaulay, V. M., Ying, S., La Thangue, N. B., D’Angiolella, V., Ryan, A. J., & Humphrey, T. C.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 28
- Issue
- 5
- Pages
- 557-568
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2181205541
- Cited by
- 300
- References
- 44
- FWCI
- 11.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.